The FDA's issuance of Complete Response Letters typically indicates significant regulatory hurdles that a company must overcome before its product can be approved. In this case, the specific mention of issues related to the enrollment status of confirmatory trials for odronextamab directly impacts Regeneron's potential to bring this product to market in the expected timeline. This regulatory setback is likely to negatively affect investor sentiment in the short term, leading to a decrease in stock price.